- About Us
- Services & Solutions
- Novel Technology Platform
- Bioconjugation Discovery
- Bioconjugation Process Development
- Analytical Development
- Formulation and DP Development
- GMP mAb Intermediate and Conjugation Manufacturing
- GMP Formulation, Fill and Lyophilization
- Payload and Linker R&D and Manufacturing
- Ready-Made Payloads & Linkers
- WuXi XDC Singapore Site
- Investor Relations
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 29/10/2026
Implementing WuXiDARx™ Conjugation and Payload-Linker Technologies for Next-Generation ADCs
Qirui Fan, Hu Chen, Jingjie Huang, Zekun Wang, Lin Zhang, Ding Wei, Zili Xu, Xiaomei Li, Yaohua Hu, Tengfei Yu, Cindy Cheng, Marie Zhu
WuXi XDC (Shanghai), Co., Ltd.; WuXi Biologics (Shanghai), Co., Ltd.
Antibody drug conjugates (ADCs) have garnered increasing attention over the past decade. The next generation of ADCs are evolving through parallel innovations in target engagement and payload-linker innovations, dominated by bispecific ADCs (BsADCs) and dual-payload ADCs (dp-ADCs). Due to the increased complexity of such modalities, these programs call for precise conjugation strategies, optimized payload-linker architecture, and improved control of physicochemical properties. To address these needs, WuXi XDC has built a platform through internal development and external collaboration.
- WuXiDARx™ conjugation technology
- X-LinC connector technology
- WuXiTecan-2
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?